KRAS and lung cancer: Lastly, the role of pBRD4 in driving BETi resistance in distinct lung cancer subtypes, in particular BRD4-fusion NUT midline carcinomas, as well as other cancers types with MYC-independent JQ1 sensitivity and driver gene mutations common to LAC—for example KRAS mutant pancreatic cancer24—warrants investigation and should be further explored.